Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review

BACKGROUND: A shift in biochemical research towards drugs for rare diseases has created new challenges for the pharmaceutical industry, government regulators, health technology assessment agencies, and public and private payers. In this article, we aim to comprehensively review, characterize, identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Janoudi, Ghayath, Amegatse, William, McIntosh, Brendan, Sehgal, Chander, Richter, Trevor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134221/
https://www.ncbi.nlm.nih.gov/pubmed/27908281
http://dx.doi.org/10.1186/s13023-016-0539-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134221/
https://www.ncbi.nlm.nih.gov/pubmed/27908281
http://dx.doi.org/10.1186/s13023-016-0539-3

Ejemplares similares